New combo approach aims to prevent transplant complications in myelofibrosis patients
NCT ID NCT07228624
First seen Nov 15, 2025 · Last updated May 01, 2026 · Updated 15 times
Summary
This study is for older adults with myelofibrosis or related blood cancers who are getting a donor stem cell transplant. Researchers want to see if adding the drug ruxolitinib to standard anti-rejection medicines can lower the risk of graft-versus-host disease (GVHD), a serious side effect where donor cells attack the body. About 50 participants will receive ruxolitinib before, during, and after transplant, along with chemotherapy and standard GVHD prevention. The main goal is to see if this combination reduces the need for strong immune-suppressing drugs after transplant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY MYELOFIBROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fred Hutch/University of Washington Cancer Consortium
RECRUITINGSeattle, Washington, 98109, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.